<?xml version="1.1" encoding="utf-8"?>
<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">JCNR</journal-id><journal-title-group><journal-title>Journal of Clinical and Nursing Research</journal-title></journal-title-group><issn>2208-3685</issn><eissn>2208-3693</eissn><publisher><publisher-name>Bio-Byword Scientific Publishing Pty. Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.26689/jcnr.v9i6.11048</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title>Mechanistic Study of Trimebutine Combined with Berberine Hydrochloride in PI-IBS Rat Intervention via the Brain–Gut–Microbiota Axis</title><url>https://artdesignp.com/journal/JCNR/9/6/10.26689/jcnr.v9i6.11048</url><author>MiaoChen,MiaoDaxing</author><pub-date pub-type="publication-year"><year>2025</year></pub-date><volume>9</volume><issue>6</issue><history><date date-type="pub"><published-time>2025-07-07</published-time></date></history><abstract>This study explored the therapeutic effect of trimebutine maleate dispersible tablets combined with berberine on PI-IBS rats with liver depression and spleen deficiency. Fifty male rats were divided into five groups: normal, model, berberine (XB), trimebutine (QM), and combination (XB+QM). The PI-IBS model was established using maternal separation, TNBS perfusion, and chronic restraint. After 20 days of drug intervention, DAI, CMDI, TDI, AWR scores, histopathology, and expression levels of c-Fos, VIP, NOS, and CHAT in the hippocampus and colon were assessed. The model group showed significant gut and brain changes, while the combination group (XB+QM) improved fecal characteristics, reduced inflammation, regulated brain-gut peptide expression, and alleviated visceral hypersensitivity and colon tissue damage (P &amp;lt; 0.05).</abstract><keywords/></article-meta></front><body/><back><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><p>Drossman DA, Hasler WL, 2016, Rome IV–Functional GI Disorders: Disorders of Gut–Brain Interaction. Gastroenterology, 150(6): 1257–1261. doi: 10.1053/j.gastro.2016.03.035.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B2" content-type="article"><label>2</label><element-citation publication-type="journal"><p>Zhang L, Duan L, Liu Y, et al., 2014, A Meta-Analysis of the Prevalence and Risk Factors of Irritable Bowel Syndrome in Chinese Community. Zhonghua Nei Ke Za Zhi, 53(12): 969.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B3" content-type="article"><label>3</label><element-citation publication-type="journal"><p>Sadeghi A, Biglari M, Moghaddam SN, 2019, Post-Infectious Irritable Bowel Syndrome: A Narrative Review. Middle East Journal of Digestive Diseases, 11(2): 69.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B4" content-type="article"><label>4</label><element-citation publication-type="journal"><p>Lee JY, Kim N, Park JH, et al., 2020, Expression of Neurotrophic Factors, Tight Junction Proteins, and Cytokines According to the Irritable Bowel Syndrome Subtype and Sex. Journal of Neurogastroenterology and Motility, 26(1): 106.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B5" content-type="article"><label>5</label><element-citation publication-type="journal"><p>Mukhtar K, Nawaz H, Abid S, 2019, Functional Gastrointestinal Disorders and Gut–Brain Axis: What Does the Future Hold? World Journal of Gastroenterology, 25(5): 552.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B6" content-type="article"><label>6</label><element-citation publication-type="journal"><p>Barbara G, Grover M, Bercik P, et al., 2019, Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome. Gastroenterology, 156(1): 46–58.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B7" content-type="article"><label>7</label><element-citation publication-type="journal"><p>Hellstrom PM, 2019, Pathophysiology of the Irritable Bowel Syndrome – Reflections of Today. Best Practice &amp; Research Clinical Gastroenterology, 40: 101620.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B8" content-type="article"><label>8</label><element-citation publication-type="journal"><p>Ford AC, Lacy BE, Talley NJ, 2017, Irritable Bowel Syndrome. New England Journal of Medicine, 376: 2566–2578.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B9" content-type="article"><label>9</label><element-citation publication-type="journal"><p>Lin G, Wang J, Ge J, 2017, Practical Internal Medicine. People’s Medical Publishing House, Beijing.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B10" content-type="article"><label>10</label><element-citation publication-type="journal"><p>Tang C, Zhang S, 2015, Internal Medicine, Digestive Medicine. People’s Medical Publishing House, Beijing.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B11" content-type="article"><label>11</label><element-citation publication-type="journal"><p>Yu J, Lao H, 2012, Observation on the Therapeutic Effect of Berberine Combined With Compound Glutamine in the Treatment of 36 Cases of Diarrhea-Predominant Irritable Bowel Syndrome. Journal of Guangdong Medical College, 30(4): 427–428.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B12" content-type="article"><label>12</label><element-citation publication-type="journal"><p>Osadchiy V, Martin CR, Mayer EA, 2019, The Gut–Brain Axis and the Microbiome: Mechanisms and Clinical Implications. Clinical Gastroenterology and Hepatology, 17(2): 322–332.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B13" content-type="article"><label>13</label><element-citation publication-type="journal"><p>Jiang T, Niu R, Liu Q, et al., 2022, Effects of Wenshen Jianpi Prescription on Visceral Sensitivity and c-Fos Expression in Rats With Diarrhea-Type Irritable Bowel Syndrome With Spleen and Kidney Yang Deficiency Based on “Gut–Brain Interaction”. Chinese Journal of Traditional Chinese Medicine Information, 29(10): 96–102. DOI:10.19879/j.cnki.1005-5304.202202209.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B14" content-type="article"><label>14</label><element-citation publication-type="journal"><p>Feng W, Wu H, Luo C, 2016, Effects of Traditional Chinese Medicine on c-Fos Expression in Irritable Bowel Syndrome. Chinese Journal of Traditional Chinese Medicine, 34(10): 2343–2345. DOI:10.13193/j.issn.1673-7717.2016.10.010.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B15" content-type="article"><label>15</label><element-citation publication-type="journal"><p>Li Q, Su H, Chen Z, et al., 2023, Observation on the Efficacy of Linaclotide Combined With Xiaoyaosan in the Treatment of Constipation-Type Irritable Bowel Syndrome and Its Effect on Plasma 5-HT and VIP. Chinese Journal of Traditional Chinese Medicine and Pharmacy, 30(5): 898–900.</p><pub-id pub-id-type="doi"/></element-citation></ref></ref-list></back></article>
